Øystein
Fluge
Researcher
Visit Address:
Haukeland universitetssykehus, Laboratoriebygget
5021 Bergen
Postal Address:
Postboks 7804
5021 Bergen
Phone:
+47 55 97 35 87
E-mail:
Journal articles
- 2013. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Annals of Oncology. 24: 1385-1392. doi: 10.1093/annonc/mds621
- 2013. Pseudoprogression in high-grade glioma. Acta Neurologica Scandinavica. 127: 31-37. doi: 10.1111/ane.12047
- 2012. Use of exon-based transcriptome profiling to identify novel signaling pathways and survival-associated genes in diffuse large B-cell lymphoma. Journal of Clinical Oncology. 30. 1 pages.
- 2012. Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients. British Journal of Cancer. 106: 756-762. doi: 10.1038/bjc.2011.548
- 2012. Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. British Journal of Cancer. 107: 1684-1691. doi: 10.1038/bjc.2012.463
- 2012. High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy. European Journal of Haematology. 89: 395-402. doi: 10.1111/ejh.12005
- 2011. High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. British Journal of Haematology. 152: 600-610. doi: 10.1111/j.1365-2141.2010.08519.x
- 2011. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLoS ONE. 6. 13 pages. doi: 10.1371/journal.pone.0026358
- 2011. (18)FDG PET/CT AFTER INTENSIFIED CHEMO-IMMUNOTHERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), AGED 18-65 YEARS WITH AAIPI 2-3. POSITIVE OR INDETERMINATE LESIONS HAVE A LOW POSITIVE PREDICTIVE VALUE. A NORDIC PHASE II SUBSTUDY. Annals of Oncology. 22: 159-159.
- 2011. MicroRNA-15b is induced with E2F-controlled genes in HPV-related cancer. British Journal of Cancer. 105: 1719-1725. doi: 10.1038/bjc.2011.457
- 2010. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of Neuro-Oncology. 96: 393-402. doi: 10.1007/s11060-009-9976-3
- 2010. R-CHOEP-14 x 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2-3: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18-65 Years. Blood. 116: 1157-1157.
- 2010. Exon Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose-Dense Chemoimmuno-therapy and CNS Prophylaxis. Results From a Nordic Lymphoma Group Phase II Study. Blood. 116: 1281-1281.
- 2010. Exon-Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B-Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose-Dense Chemoimmuno-therapy and CNS Prophylaxis. Results From a Nordic Lymphoma Group Phase II Study. Blood. 116: 1281-1281.
- 2010. High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Dose-Dense Chemoimmunotherapy and Systemic CNS Prophylaxis. Results From a Nordic Phase II Study. Blood. 116: 1686-1686.
- 2009. Kinetics study on markers of the immune system by gene expression profiling of an in vivo heated tumor. International Journal of Hyperthermia. 25: 41-46. doi: 10.1080/02656730802397955
- 2009. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncologica. 48: 368-376. doi: 10.1080/02841860902755244
- 2009. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. British Journal of Cancer. 101: 1282-1289. doi: 10.1038/sj.bjc.6605333
- 2009. Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series. BMC Neurology. 9. 7 pages. doi: 10.1186/1471-2377-9-28
- 2008. Global gene expression analyses reveal changes in biological processes after hyperthermia in a rat glioma model. International Journal of Hyperthermia. 24: 425-441. doi: 10.1080/02656730802081997
- 2008. Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour. Radiotherapy and Oncology. 86: 435-442. doi: 10.1016/j.radonc.2008.01.022
- 2008. Gene expression reveals two distinct groups of anal carcinomas with clinical implications. British Journal of Cancer. 98: 1264-1273. doi: 10.1038/sj.bjc.6604285
- 2008. Current status of antivascular therapy and targeted treatment in the clinic. International Journal of Hyperthermia. 24: 97-110. doi: 10.1080/02656730701824406
- 2008. Analkreft. Tidsskrift for Den norske legeforening. 128: 198-200.
- 2006. Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid. 16: 161-175.
- 1998. Fish consumption and respiratory symptoms among young adults in a Norwegian community. European Respiratory Journal. 12: 336-340.
- 1998. Hospitalization for lung disease in early childhood and asthma symptoms in young adulthood. Respiratory Medicine. 92: 1003-1009.
Reports and theses
- 2004. Gene expression in papillary thyroid carcinomas, with special reference to tyrosine kinase receptors and growth factors.
Book sections
- 2009. Kreftceller og kjemoterapi. Kapittel 1, pages 13-37. In:
- 2009. Medikamentell kreftbehandling. 495 pages. ISBN: 978-829923312-5.
- 2006. Thyroid Cancer: Molecular Biology and Clinical Aspects. 20, pages 431-444. In:
- 2006. Molecular carcinogenesis and the molecular biology of human cancer. CRC Press. 576 pages. ISBN: 0-8493-1167-5.
More information in national current research information system (CRIStin)